Navigation Links
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Date:11/24/2008

with peginterferon (without ribavirin), demonstrated enhanced antiviral activity, with up to 4 log10 and 5 log10 decreases in circulating HCV, respectively.

Full results of the boceprevir HCV SPRINT-1 study and early phase clinical results with SCH 900518 are being submitted for presentation at a future medical meeting.

About the Boceprevir HCV SPRINT-1 Study

In this Phase II study, known as HCV SPRINT-1 (HCV Serine Protease Inhibitor Therapy-1), boceprevir (800 mg TID) was evaluated in three treatment regimens: 4 weeks of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) therapy followed by the addition of boceprevir to the combination for 24 or 44 weeks (totaling 28 or 48 weeks of treatment), boceprevir in combination with PEGINTRON and REBETOL at the doses described above for 28 or 48 weeks, and, in Part II of the study, boceprevir in combination with PEGINTRON and low-dose REBETOL (400-1000 mg daily based on patient weight) for 48 weeks, compared to a control of PEGINTRON (1.5 mcg/kg once weekly) and REBETOL (800-1400 mg daily based on patient weight) alone for 48 weeks (an approved treatment regimen). The primary endpoint of the study is SVR after 24 weeks of follow up (SVR 24). SVR rates are not yet available for Part II of this study evaluating boceprevir with low-dose REBETOL (n=59) compared to contemporaneous control (n=16) as described above.

About Boceprevir Phase III Studies

Schering-Plough is conducting two large ongoing pivotal Phase III studies of boceprevir in patients chronically infected with HCV genotype 1. One study is in treatment-naive patients and the other in patients who failed prior treatment (relapsers and nonresponders). The two randomized, double-blind, placebo-controlled studies evaluate the efficacy of boceprevir in combination with PEGINTRON and REBETOL compared to standard of care
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention
2. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
3. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
4. Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
5. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
8. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
9. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
10. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
11. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... 17, 2013 Oramed Pharmaceuticals Inc. ... drug delivery systems, announced today that the United States ... Investigational New Drug application(IND) for ORMD-0801, its oral insulin ... the FDA clearance to proceed," stated Nadav ... is a major milestone for Oramed and we look ...
(Date:5/16/2013)... NORTH CHICAGO, Ill. and MECHELEN, ... NV (Euronext: GLPG) and AbbVie (NYSE: ABBV ... development collaboration to include Crohn,s disease.  Galapagos will fund ... which is designed to facilitate rapid progression into Phase ... Q2 2015, AbbVie will pay Galapagos $50 million.  The ...
(Date:5/16/2013)... SYDNEY , May 16, 2013  HeartWare International, ... leading innovator of less invasive, miniaturized circulatory support technologies that ... that CEO Doug Godshall is scheduled ... 11:00 a.m. EDT on Monday, May 20, 2013.  The conference ... York Hotel. A live webcast of the Company,s ...
Breaking Medicine Technology:Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
... , CARY, N.C., Nov. 20 Cornerstone Therapeutics Inc. ... on acquiring, developing and commercializing significant products primarily for ... had received a Warning Letter from the Food and ... tablets (Phenylephrine HCl 10 mg, Pyrilamine Maleate 16 mg) ...
... , HARRISBURG, Pa., Nov. 20 The Department ... priority groups that did not have previous access to the vaccine. , ... Friday,s clinic hours are from 2 p.m. to 8 p.m. Hours on ... Nov. 22, the clinics will operate from 2 p.m. to 8 p.m. ...
Cached Medicine Technology:Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 2Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal 3Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available 2
(Date:5/18/2013)... California (PRWEB) May 18, 2013 Online watch ... be Rolex watch owners at a fraction of ... of luxury timepieces in the world, buyers are urged to ... compared to buying a Rolex watch from a brick-and-mortar store, ... owned Rolex watches priced at unbelievable rates. Although some ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay ... latest edition of what is considered the "bible" of ... changes continues. "This is unprecedented, the amount of ... president-elect of the American Psychiatric Association (APA). "It,s been ... is. You have to evaluate it and then make ...
(Date:5/18/2013)... a few extra cups of coffee each month might ... known as primary sclerosing cholangitis (PSC), a new study ... Minn., found that drinking coffee was associated with a ... to cirrhosis of the liver, liver failure and biliary ... relationship. "While rare, PSC has extremely detrimental ...
(Date:5/18/2013)... Orlando, FL (May 18, 2013) The use ... for a colonoscopy, according to new research presented ... process, which begins days in advance of the ... preparation medication to be taken at strict intervals. ... for doctors to see cancer and precancerous polyps ...
(Date:5/18/2013)... is associated with a reduced risk of primary ... Clinic research shows. The findings were being presented ... Orlando, Fla. , PSC is an inflammatory ... inflammation and subsequent fibrosis that can lead to ... cancer. , "While rare, PSC has extremely detrimental ...
Breaking Medicine News(10 mins):Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2Health News:New smartphone application improves colonoscopy preparation 2
... brain seen in people with Alzheimer's disease has been ... their cognitive abilities and become unusually forgetful. ,The ... who may develop Alzheimer's disease.Alzhiemer’s disease results in memory ... in the USA are estimated to suffer from this ...
... of Disease in Childhood recently published a study which proves ... hand-eye coordination of toddlers.// ,The trial was done ... fish oil/olive oil supplements from 20th week of their pregnancy ... and those who did not routinely eat more than two ...
... encephalopathy may need to get cooler at the top, to ... during birth. Such babies can now be helped with a ... damage. This product has been approved by the Food and ... device with the brand name of ‘Cool-Cap’ may be a ...
... the rules governing the private educational institutions in the ... ,The state cabinet decided to adopt the new rules ... an official said here. ,The school managements ... students, pay prescribed and timely salaries to teaching and ...
... study has indicated that inflammatory bowel disease in women could ... times.// , ,Diseases such as Crohn's disease and ulcerative ... babies or premature babies. Yet, the 'silver lining' exists in ... certainly reduced the risks. ,The St. Mary's ...
... January issue of the medical journal Otolaryngology- Head and Neck ... permanent long-term hearing loss that can be caused by exposure ... measured the impact of “impulse noise” (short bursts of acoustic ... by using short-term exposure to the impulse noise generated by ...
Cached Medicine News:Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 2Health News:Novel Brain Scan to Diagnose Alzheimer's Disease 3Health News:Fish Oil Improves Toddler’s Hand-eye Coordinatio 2
Disposable tracheostomy care tray....
Disposable tracheostomy care tray....
... Has the Right Solution For Your Tracheostomy ... and care tray features the latest components ... important infection control task. Designed by clinicians, ... needs of each patient and caregiver. All ...
... Has the Right Solution For Your Tracheostomy ... and care tray features the latest components ... important infection control task. Designed by clinicians, ... needs of each patient and caregiver. All ...
Medicine Products: